| Popis: |
Summary Clinical experience with a new drug, tridione, over a period of 16 months in 75 patients with convulsive and related disorders has left us with the following impressions: 1. It is the most effective drug yet employed in the treatment of petit mal. 2. Its anticonvulsant effect in the control of grand mal attacks is not as great as that of dilantin sodium, phenobarbital, or the bromides. It may occasionally be of value as an adjuvant or additional remedy in the control of major attacks not adequately controlled by other drugs. 3. It is more effective in idiopathic than in organic epilepsy. 4. It is of value in reducing the tension or rigidity of patients with cerebral palsy. Of these, the athetoids are benefited more than the spastics. 5. It may be of value in the temporary control of children with behavior disturbances. 6. It is of possible value in the control of the convulsions and respiratory spasms of tetanus when given intravenously. 7. It is of no particular value in chorea, Parkinsonism, or dystonia musculorum. Regarding its clinical pharmacologic properties, it has been our experience that: a. Tridione is a safe drug to use since no permanent deleterious effects, addiction, or tolerance were noted. b. Toxic symptoms are usually mild and consist of photophobia, visual blurring, dizziness, and nausea. They occur more commonly in adults than in children and disappear promptly when the drug is withdrawn. c. Sudden stopping of the drug in epilepsy does not result in status epilepticus. d. When used in combination, it is more effective with phenobarbital than dilantin. e. Chronic alcoholism increases the tolerance to the drug. f. Since it is least effective in lesions of the pyramidal system and more effective in certain conditions with extrapyramidal lesions, it is suggested that its site of action is probably in the midbrain, and/or areas in the basal nuclei, and/or upon the cortical connecting tracts of these areas. |
